Editas Medicine Inc. Insider Trading

EDIT

Last 12 months

Insiders sold 107K and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in May 2024.

Net open-market

−107K

0 buys · 14 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

May 2024

May 13, 2024

Get an email when EDIT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 3	Amy Parison SVP, Chief Financial Officer	Sold10b5-1 plan	453	$3.04	1K	3.2%	Form 4
Sep 3	Linda Burkly EVP, Chief Scientific Officer	Sold10b5-1 plan	709	$3.04	2K	1.1%	Form 4
Sep 3	Gilmore Neil O'Neill CEO	Sold10b5-1 plan	5,124	$3.04	16K	2.1%	Form 4
Aug 3	Amy Parison SVP, Chief Financial Officer	Sold10b5-1 plan	678	$2.58	2K	4.5%	Form 4
Jul 28	Linda Burkly EVP, Chief Scientific Officer	Sold10b5-1 plan	4,928	$2.67	13K	7.3%	Form 4
Jun 3	Amy Parison SVP, Chief Financial Officer	Sold10b5-1 plan	464	$2.70	1K	3.0%	Form 4
Jun 3	Gilmore Neil O'Neill CEO	Sold10b5-1 plan	15,380	$2.70	42K	5.8%	Form 4
Jun 3	Linda Burkly EVP, Chief Scientific Officer	Sold10b5-1 plan	731	$2.70	2K	1.1%	Form 4
Mar 3	Gilmore Neil O'Neill CEO	Sold10b5-1 plan	5,394	$2.02	11K	2.0%	Form 4
Mar 3	Amy Parison SVP, Chief Financial Officer	Sold10b5-1 plan	474	$2.02	$957	3.0%	Form 4
Mar 3	Linda Burkly EVP, Chief Scientific Officer	Sold10b5-1 plan	749	$2.02	2K	1.1%	Form 4
Dec 3, 2025	Linda Burkly EVP, Chief Scientific Officer	Sold10b5-1 plan	713	$2.15	2K	1.0%	Form 4
Dec 3, 2025	Gilmore Neil O'Neill CEO	Sold10b5-1 plan	5,603	$2.15	12K	2.0%	Form 4
Dec 3, 2025	Amy Parison SVP, Chief Financial Officer	Sold10b5-1 plan	461	$2.15	$991	2.8%	Form 4
Sep 3, 2025	Linda Burkly EVP, Chief Scientific Officer	Sold10b5-1 plan	710	$2.60	2K	1.0%	Form 4
Sep 3, 2025	Amy Parison SVP, Chief Financial Officer	Sold10b5-1 plan	458	$2.60	1K	2.7%	Form 4
Sep 3, 2025	Gilmore Neil O'Neill CEO	Sold10b5-1 plan	5,592	$2.60	15K	2.0%	Form 4
Aug 7, 2025	Amy Parison SVP, Chief Financial Officer	Sold10b5-1 plan	679	$2.58	2K	3.9%	Form 4
Jul 31, 2025	Linda Burkly EVP, Chief Scientific Officer	Sold10b5-1 plan	5,121	$2.49	13K	7.4%	Form 4
Jun 3, 2025	Amy Parison SVP, Chief Financial Officer	Sold10b5-1 plan	446	$1.72	$767	2.5%	Form 4
Jun 3, 2025	Linda Burkly EVP, Chief Scientific Officer	Sold10b5-1 plan	726	$1.72	1K	1.0%	Form 4
Jun 3, 2025	Gilmore Neil O'Neill CEO	Sold10b5-1 plan	15,192	$1.72	26K	5.1%	Form 4
Mar 4, 2025	Erick Lucera EVP, Chief Financial Officer	Sold10b5-1 plan	4,109	$1.71	7K	3.5%	Form 4
Mar 4, 2025	Gilmore Neil O'Neill CEO	Sold10b5-1 plan	16,632	$1.71	28K	5.3%	Form 4
Mar 4, 2025	Linda Burkly EVP, Chief Scientific Officer	Sold10b5-1 plan	2,891	$1.71	5K	4.0%	Form 4
Dec 3, 2024	Gilmore Neil O'Neill CEO	Sold10b5-1 plan	1,618	$2.08	3K	0.5%	Form 4
Dec 3, 2024	Baisong Mei EVP, Chief Medical Officer	Sold10b5-1 plan	541	$2.08	1K	0.4%	Form 4

Sep 310b5-1 plan
Amy Parison
SVP, Chief Financial Officer · sold 453 at $3.04
1K
3.2% of stake
Sep 310b5-1 plan
Linda Burkly
EVP, Chief Scientific Officer · sold 709 at $3.04
2K
1.1% of stake
Sep 310b5-1 plan
Gilmore Neil O'Neill
CEO · sold 5,124 at $3.04
16K
2.1% of stake
Aug 310b5-1 plan
Amy Parison
SVP, Chief Financial Officer · sold 678 at $2.58
2K
4.5% of stake
Jul 2810b5-1 plan
Linda Burkly
EVP, Chief Scientific Officer · sold 4,928 at $2.67
13K
7.3% of stake
Jun 310b5-1 plan
Amy Parison
SVP, Chief Financial Officer · sold 464 at $2.70
1K
3.0% of stake
Jun 310b5-1 plan
Gilmore Neil O'Neill
CEO · sold 15,380 at $2.70
42K
5.8% of stake
Jun 310b5-1 plan
Linda Burkly
EVP, Chief Scientific Officer · sold 731 at $2.70
2K
1.1% of stake
Mar 310b5-1 plan
Gilmore Neil O'Neill
CEO · sold 5,394 at $2.02
11K
2.0% of stake
Mar 310b5-1 plan
Amy Parison
SVP, Chief Financial Officer · sold 474 at $2.02
$957
3.0% of stake
Mar 310b5-1 plan
Linda Burkly
EVP, Chief Scientific Officer · sold 749 at $2.02
2K
1.1% of stake
Dec 3, 202510b5-1 plan
Linda Burkly
EVP, Chief Scientific Officer · sold 713 at $2.15
2K
1.0% of stake
Dec 3, 202510b5-1 plan
Gilmore Neil O'Neill
CEO · sold 5,603 at $2.15
12K
2.0% of stake
Dec 3, 202510b5-1 plan
Amy Parison
SVP, Chief Financial Officer · sold 461 at $2.15
$991
2.8% of stake
Sep 3, 202510b5-1 plan
Linda Burkly
EVP, Chief Scientific Officer · sold 710 at $2.60
2K
1.0% of stake
Sep 3, 202510b5-1 plan
Amy Parison
SVP, Chief Financial Officer · sold 458 at $2.60
1K
2.7% of stake
Sep 3, 202510b5-1 plan
Gilmore Neil O'Neill
CEO · sold 5,592 at $2.60
15K
2.0% of stake
Aug 7, 202510b5-1 plan
Amy Parison
SVP, Chief Financial Officer · sold 679 at $2.58
2K
3.9% of stake
Jul 31, 202510b5-1 plan
Linda Burkly
EVP, Chief Scientific Officer · sold 5,121 at $2.49
13K
7.4% of stake
Jun 3, 202510b5-1 plan
Amy Parison
SVP, Chief Financial Officer · sold 446 at $1.72
$767
2.5% of stake
Jun 3, 202510b5-1 plan
Linda Burkly
EVP, Chief Scientific Officer · sold 726 at $1.72
1K
1.0% of stake
Jun 3, 202510b5-1 plan
Gilmore Neil O'Neill
CEO · sold 15,192 at $1.72
26K
5.1% of stake
Mar 4, 202510b5-1 plan
Erick Lucera
EVP, Chief Financial Officer · sold 4,109 at $1.71
7K
3.5% of stake
Mar 4, 202510b5-1 plan
Gilmore Neil O'Neill
CEO · sold 16,632 at $1.71
28K
5.3% of stake
Mar 4, 202510b5-1 plan
Linda Burkly
EVP, Chief Scientific Officer · sold 2,891 at $1.71
5K
4.0% of stake
Dec 3, 202410b5-1 plan
Gilmore Neil O'Neill
CEO · sold 1,618 at $2.08
3K
0.5% of stake
Dec 3, 202410b5-1 plan
Baisong Mei
EVP, Chief Medical Officer · sold 541 at $2.08
1K
0.4% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch EDIT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with EDIT

CompareIntrinsic value

STROSutro Biopharma, Inc.

$9.94+4.52%10

DTILPrecision Biosciences Inc.

$7.89+13.20%48

PTHSPelthos Therapeutics Inc.

$10.15-5.84%0

CHRSCoherus Biosciences Inc.

$0.85+5.46%10

IVVDInvivyd Inc.

$0.63+8.93%10

CCCCC4 Therapeutics Inc.

$3.12-2.80%33

FENCFennec Pharmaceuticals Inc.

$10.35-3.27%40

SGMOSangamo Therapeutics Inc.

$0.12-0.20%10

Held by ETFs

EDIT is in 17 US ETFs. The largest of them, with EDIT's weight in each:

Spot a number that looks wrong? Check it in EDIT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing EDIT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.